NO20053947L - Forbedrede antitumorale behandlinger. - Google Patents

Forbedrede antitumorale behandlinger.

Info

Publication number
NO20053947L
NO20053947L NO20053947A NO20053947A NO20053947L NO 20053947 L NO20053947 L NO 20053947L NO 20053947 A NO20053947 A NO 20053947A NO 20053947 A NO20053947 A NO 20053947A NO 20053947 L NO20053947 L NO 20053947L
Authority
NO
Norway
Prior art keywords
improved antitumoral
antitumoral treatments
treatments
improved
treatment
Prior art date
Application number
NO20053947A
Other languages
English (en)
Other versions
NO20053947D0 (no
Inventor
Jose Jimeno
Debabrata Barnejee
Joseph R Bertino
Saydam Guray
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20053947D0 publication Critical patent/NO20053947D0/no
Publication of NO20053947L publication Critical patent/NO20053947L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sammendrag Aplidin og aplidinanaloger kan benyttes for behandling av cancer, særlig for behandling av leukemier og lymfomer, og særlig ved kombinasjonsterapi.
NO20053947A 2003-03-12 2005-08-24 Forbedrede antitumorale behandlinger. NO20053947L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
PCT/US2004/007606 WO2004080421A2 (en) 2003-03-12 2004-03-12 Improved antitumoral treatments

Publications (2)

Publication Number Publication Date
NO20053947D0 NO20053947D0 (no) 2005-08-24
NO20053947L true NO20053947L (no) 2005-12-07

Family

ID=32990868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053947A NO20053947L (no) 2003-03-12 2005-08-24 Forbedrede antitumorale behandlinger.

Country Status (13)

Country Link
US (2) US7576188B2 (no)
EP (1) EP1620117A4 (no)
JP (1) JP2006519848A (no)
KR (1) KR20060002778A (no)
CN (3) CN101579520A (no)
AU (1) AU2004220451B2 (no)
CA (1) CA2516572A1 (no)
MX (1) MXPA05009741A (no)
NO (1) NO20053947L (no)
NZ (1) NZ541634A (no)
RU (1) RU2341283C2 (no)
UA (2) UA83022C2 (no)
WO (1) WO2004080421A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
IL149488A0 (en) * 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
WO2008135793A1 (en) * 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
WO2010029158A1 (en) * 2008-09-12 2010-03-18 Pharma Mar, S.A. Aplidine in the treatment of chronic myeloproliferative disorders
CN104706599B (zh) * 2013-12-11 2020-10-02 中国海洋大学 一种携带膜海鞘素化合物的冻干粉针剂
SG10201913290QA (en) * 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5018188A (en) 1989-12-20 1991-05-21 Motorola, Inc. Microphone-controller with multifunction, single conductor
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5482726A (en) * 1992-07-14 1996-01-09 Us Harvest Technologies Corporation Method for reducing contamination of shellfish
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
AU3353897A (en) 1996-07-03 1998-02-02 Mckechnie Uk Limited Container
JP2001504814A (ja) 1996-10-24 2001-04-10 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニンＡのアミノＨｉｐ類似体の全合成
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
WO1998050048A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9821975D0 (en) * 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
IL149488A0 (en) * 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
SE9904175D0 (sv) 1999-11-18 1999-11-18 Pharmacia & Upjohn Diag Ab Assay device and use thereof
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
WO2002030441A2 (en) 2000-10-12 2002-04-18 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
CA2435418A1 (en) * 2001-01-24 2002-08-01 Mestex Ag Use of neurotoxic substances in producing a medicament for treating joint pains
ATA13422001A (de) 2001-08-23 2003-09-15 Plasser Bahnbaumasch Franz Maschine zur bearbeitung einer gleisbettung
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료

Also Published As

Publication number Publication date
WO2004080421A2 (en) 2004-09-23
AU2004220451A1 (en) 2004-09-23
US20060178298A1 (en) 2006-08-10
RU2005126819A (ru) 2006-01-20
MXPA05009741A (es) 2005-11-16
WO2004080421A3 (en) 2005-06-09
UA82089C2 (uk) 2008-03-11
NO20053947D0 (no) 2005-08-24
AU2004220451B2 (en) 2010-01-21
CN1761480B (zh) 2012-09-26
JP2006519848A (ja) 2006-08-31
US7576188B2 (en) 2009-08-18
CN1753684A (zh) 2006-03-29
CN1761480A (zh) 2006-04-19
NZ541634A (en) 2008-08-29
EP1620117A4 (en) 2009-07-29
UA83022C2 (uk) 2008-06-10
CA2516572A1 (en) 2004-09-23
EP1620117A2 (en) 2006-02-01
CN101579520A (zh) 2009-11-18
KR20060002778A (ko) 2006-01-09
CN100409895C (zh) 2008-08-13
US20090227490A1 (en) 2009-09-10
RU2341283C2 (ru) 2008-12-20

Similar Documents

Publication Publication Date Title
MX2023009135A (es) Compuestos de oxazepina tetraciclica y usos de estos.
TW200612918A (en) Lonidamine analogs
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2004080421A3 (en) Improved antitumoral treatments
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
TW200503751A (en) Methods for treating sinus headache
WO2006081510A3 (en) Methods for treating renal cell carcinoma
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
WO2002076548A3 (en) Methods and apparatus for treating diseased tissue
EP1628667A4 (en) METHOD FOR TREATING DISEASES USING HSP90 INHIBITION AGENTS COMBINED WITH ANTIMITOTICS
WO2020123543A3 (en) Models and methods useful for the treatment of serrated colorectal cancer
TW200616639A (en) Methods for treating a mammal before, during and after cardiac arrest
WO2007047608A3 (en) Fibrin targeted therapeutics
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
NO20054668L (no) Aplidin for multippelt myelom-behandling
EP4349410A3 (en) A composition for use in the therapeutic treatment of a cancer or a tumor
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
ATE442188T1 (de) Bestrahlungseinrichtung
IL159770A0 (en) Calcium salts with cytotoxic activity
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
TR200302193T4 (tr) Kombinasyon kemoterapisi.
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application